Background
==========

Crohn's disease (CD), a subtype of inflammatory bowel disease, is a chronic and relapsing disease affecting the entire gastrointestinal tract with systemic manifestations. The etiology of CD is incompletely understood, although multiple factors have been reported to contribute to the onset of disease. Symptoms of CD can be severe, including abdominal pain, diarrhea, gastrointestinal bleeding, abdominal distension, weight loss, malnutrition and several extra-intestinal manifestations and complications \[[@b1-medscimonit-26-e925018]\]. One of the most frequent complications of CD is perianal fistula (PF), which is strongly associated with increased rates of hospitalization, intestinal resection, and disease recurrence \[[@b2-medscimonit-26-e925018]\], making PF a predictor of poor long-term outcomes in CD patients.

Advances in treatment, including the anti-TNF-α antibody Infliximab (IFX), have led to profound improvements in CD treatment strategies. IFX has been shown to promote mucosal healing and long-term maintenance of remission. A multicenter, randomized trial found that IFX induction therapy was effective in treating CD patients with PF \[[@b3-medscimonit-26-e925018]\], and the ACCENT II maintenance trial showed that IFX 5 mg/kg body weight every 8 weeks maintained disease response for 54 weeks in 36% of patients with fistulizing CD \[[@b4-medscimonit-26-e925018]\].

In addition to physical impairments, CD patients experience reduced health-related quality of life (QoL) \[[@b5-medscimonit-26-e925018],[@b6-medscimonit-26-e925018]\], a negative body image (BI) and lower self-esteem (SE) \[[@b7-medscimonit-26-e925018]--[@b9-medscimonit-26-e925018]\], which negatively affect their social-psychological well-being. Few studies, however, have assessed the social and psychological effects experienced by CD patients with PF. Moreover, the effects of IFX on the social-psychological status of CD patients with PF have not been determined. The present study therefore assessed whether the presence of active PF (APF) could directly influence QoL, BI and SE of CD patients, and whether IFX could ameliorate their social-psychological impairments.

Material and Methods
====================

Patient enrollment
------------------

This study was approved by the ethics committee of Shanghai Ruijin Hospital. Information about treatment-naïve patients diagnosed with CD between September 2016 and August 2018 by the gastroenterology service of Shanghai Ruijin Hospital were retrospectively collected from the hospital's CD patient database. The diagnosis of CD was based on patients' clinical symptoms, serologic tests, endoscopic examinations and pathologic results. The data retrieved at the time of CD diagnosis included age at diagnosis, gender, level of education, marital status, level of family income, body mass index (BMI), disease type according to the Montreal classification, and Harvey-Bradshaw Index (HBI). Data retrieved for patients with APF also included fistula type and severity. All of the enrolled patients had signed written informed consent forms. Patients aged \<18 or \>60 years, pregnant and lactating women, patients who also had other chronic diseases and those with incomplete baseline data were excluded. All data were stored and processed anonymously.

Short-Form of Inflammatory Bowel Disease Questionnaire (SIBDQ)
--------------------------------------------------------------

QoL was assessed using the Chinese version of the SIBDQ. The SIBDQ consists of ten questions about four dimensions of IBD: bowel (defecation frequency, abdominal pain), systemic discomfort (fatigue), social status (impact of disease on daily life) and emotional issues (concerns about surgery, anxiety). Each question was scored on a seven-point scale (1 to 7), with higher scores indicating better QoL \[[@b10-medscimonit-26-e925018]\].

Body Image Scale (BIS)
----------------------

The BIS questionnaire consists of 9 items measuring behavioral, affective, and cognitive dimensions of BI and has been validated for CD patients \[[@b7-medscimonit-26-e925018]\]. Each item is rated on a 4-point Likert scale (0 to 3). Higher scores represent more body image-related distress or body image concerns.

Rosenberg Self-Esteem Scale (RSE)
---------------------------------

General self-esteem (SE) was assessed using the 10-item RSE questionnaire. Each item on the RSE is rated on a four-point Likert scale (1 to 4), with higher scores indicating higher levels of SE \[[@b11-medscimonit-26-e925018]\].

Perianal Crohn's Disease Activity Index (PCDAI)
-----------------------------------------------

The PCDAI is a self-reported questionnaire concerning five clinical dimensions: discharge; activity restriction; sexual activity restriction; perianal disease type and degree of PF induration. Each dimension is scored from 0 to 5 points, with higher scores indicating more severe disease \[[@b12-medscimonit-26-e925018]\].

Data collection
---------------

CD patients with at least one draining PF were defined as having an APF. Treatment efficacy was assessed by clinical evaluation at each follow-up visit according to items on the HBI and PCDAI. Perianal fistula response (PFR) was defined as a ≥50% reduction from baseline in the number of draining PFs, as determined by gentle compression. All CD patients with APF were followed up for 6--12 months after diagnosis. Improvement was defined as a higher SIBDQ, lower BIS, higher RSE and lower PCDAI relative to baseline.

Matching
--------

Because BI has been associated with gender, age, BMI and support from peers or family \[[@b13-medscimonit-26-e925018],[@b14-medscimonit-26-e925018]\], positive SE has been associated with higher education level and male gender \[[@b15-medscimonit-26-e925018],[@b16-medscimonit-26-e925018]\], and reduced QoL has been associated with disease activity and phenotype \[[@b17-medscimonit-26-e925018]\], CD patients with and without APF were subjected to propensity score matching (PSM). Propensity scores were based on baseline variables, including age, gender, educational level, marital status, family income level, BMI level, disease classification and HBI index. Nearest neighbor matching was performed in a 1: 1 ratio without replacement, and caliber width was set at a standard deviation (SD) of 0.2.

Statistical analysis
--------------------

All statistical analyses were performed using the Statistical Package for the Social Sciences ver. 22.0 (SPSS, Chicago, IL). Before PSM matching, normally distributed continuous data were presented as means with SDs and were compared using independent sample t tests. Qualitative data were presented as frequency with percentage and compared using chi-square or Fisher's exact test. After PSM, normally distributed continuous data were compared using paired sample t tests. Paired sample t tests were also used to compare questionnaire scores before and after treatment of patients with APF. P-values \<0.05 were considered statistically significant.

Results
=======

Patients' demographic and clinical characteristics
--------------------------------------------------

The flowchart of this study is shown in [Figure 1](#f1-medscimonit-26-e925018){ref-type="fig"}. Data on 322 patients with CD were retrieved from the hospital database. Twenty-one of these patients were excluded, including 14 with incomplete baseline data, six with concomitant disease, and one who was pregnant. Of the 301 patients included in the primary analysis, 91 (30.2%) had APF. [Table 1](#t1-medscimonit-26-e925018){ref-type="table"} shows the baseline clinical characteristics of all included patients. Of the 91 patients with APF, three underwent surgery for severe perianal complications and two were lost to follow-up. Finally, 86 CD patients with APF were enrolled.

To analyze the impact of APF on social-psychological status, patients with CD were divided into two groups, those with and without APF. [Table 2](#t2-medscimonit-26-e925018){ref-type="table"} shows the demographic characteristics of these patients before and after PSM matching. Before PSM matching, there were no significant between-group differences in gender, educational level, marital status, income level, disease location and disease behavior according to the Montreal criteria (P\>0.05 each). However, median age was lower in patients with than without APF (33.7 years *vs.* 35.3 years, P=0.041). In addition, BMI was significantly lower (P=0.026) and HBI score significantly higher (P\<0.001) in patients with than without APF. Moreover, assessments of psychological-social status parameters showed that SIBDQ (P=0.016), RSE (P\<0.001) and BIS (P\<0.001) scores were significantly higher in CD patients with than without APF.

Because psychological-social parameters could be influenced by multiple factors, PSM of the two groups was performed to minimize the selection bias caused by psychological-social parameters ([Table 2](#t2-medscimonit-26-e925018){ref-type="table"}, matched cohort). Of all 91 patients with APF, 82 (90.1%) could be matched successfully to patient without APF according to gender, age, educational level, marital status, income level, BMI, disease location, disease behavior and HBI. Following PSM matching, there were no significant differences in baseline characteristics and SIBDQ scores between CD patients with and without APF. However, RSE scores were significantly lower (P\<0.001) and BIS scores significantly higher (P\<0.001) in CD patients with than without APF, indicating that patients with APF had a lower level of self-esteem and greater body image dissatisfaction.

PFR and psychological-social status in CD patients with APF
-----------------------------------------------------------

The clinical features of PF type and the concomitant treatment of the 86 CD patients with APF are listed in [Table 3](#t3-medscimonit-26-e925018){ref-type="table"}. Of these 86 patients, 45 (52.3%) achieved PFR, whereas 41 (47.7%) had persistent APF. However, the proportion of patients with a single PF was significantly higher in the PFR than in the non-PFR group (P=0.046). Moreover, the proportion of patients treated with IFX was significantly higher in the PFR than in the non-PFR group (P=0.005). A comparison of the changes in scores of the four questionnaires before and after treatment showed that improvements in PCDAI (P\<0.01), SIBDQ (P=0.003), RSE (P\<0.001) and BIS (P\<0.01) scores were significantly greater in the PFR than in the non-PFR group ([Table 3](#t3-medscimonit-26-e925018){ref-type="table"}, [Figure 2](#f2-medscimonit-26-e925018){ref-type="fig"}).

IFX improvement of psychological-social status in CD patients with APF
----------------------------------------------------------------------

To further analyze the role of IFX treatment in improving social-psychological status in CD patients with APF, we compared the PFR rate and the improvements in PCDAI, SIBDQ, RSE and BIS scores between the IFX and non-IFX groups ([Table 4](#t4-medscimonit-26-e925018){ref-type="table"}). In the IFX group, the PFR rate was 68.3%, which was significantly higher than in the non-IFX group (P=0.005). Furthermore, improvements in PCDAI (P= 0.003), SIBDQ (P=0.015), RSE (P=0.011) and BIS (P=0.020) scores were significantly greater in the IFX than in the non-IFX group ([Table 4](#t4-medscimonit-26-e925018){ref-type="table"}, [Figure 3](#f3-medscimonit-26-e925018){ref-type="fig"}).

Discussion
==========

Body image dissatisfaction (BID) is quite common in CD patients, with recent studies reporting BID in 21--87% of these patients \[[@b7-medscimonit-26-e925018],[@b14-medscimonit-26-e925018],[@b18-medscimonit-26-e925018]\]. Moreover, some IBD patients may be at risk of low SE \[[@b8-medscimonit-26-e925018]\], and the combination of increased BID and low SE has been associated with reduced QoL \[[@b7-medscimonit-26-e925018],[@b19-medscimonit-26-e925018]\]. To our knowledge, however, BID and SE had never been fully evaluated in CD patients with APF, nor had their improvements in response to treatment.

The present study found that CD patients with APF were younger and had lower BMI and more severe disease activity than CD patients without APF. Because BID, SE and QoL are associated with many social-clinical parameters, we performed PSM to exclude these possible interfering factors. Analysis following PSM showed that BID was higher and SE and QoL lower in CD patients with than without APF. Thus, medications that could induce PFR may improve BID, SE and QoL scores in CD patients with APF. Indeed, we found that PFR was strongly associated with improvements in BID, SE and QoL. Because IFX has been shown to induce PFR in CD patients with APF, it may also improve BID, SE and QoL in these patients.

IFX, the first biologic anti-TNFα agent approved for CD patients in China, has been shown effective in inducing deep remission of PF, resulting in clinical improvement \[[@b20-medscimonit-26-e925018]\]. Our study found that IFX treatment resulted in a PFR rate of 68.3% in CD patients with APF, a rate higher than that previously reported \[[@b4-medscimonit-26-e925018]\]. The improvement in PFR rate may be due to the synergistic effects of IFX with other concomitant medications. Induction treatment with IFX resulted in a higher level of SIBDQ and improved QoL. Similar, IFX has been shown to improve QoL in CD patients \[[@b21-medscimonit-26-e925018]--[@b23-medscimonit-26-e925018]\]. Moreover, our study revealed that IFX could significantly improve BI and SE in CD patients with APF. To our knowledge, this study is the first to show that IFX could improve overall social-psychological status in CD patients with APF.

This study had several limitations. First, although patients were compared after PSM, this study was limited by its retrospective design and the limited number of patients. Long-term, multi-center, prospective randomized controlled trials are needed to further determine the effect of IFX on improving BID, SE and QoL in CD patients with APF. Second, we did not stratify patients by time of evaluation, IFX dosing strategy, or treatment with concomitant medications.

Conclusions
===========

In conclusion, CD patients with APF experience greater BID, lower SE and poorer QoL than CD patients without APF. The presence of APF seriously affected the overall physio-psycho-social health of CD patients. IFX was shown to improve PF, thereby improving patient BID, SE and QoL.
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###### 

Baseline demographic and clinical characteristics of CD patients.

  Clinical features                           CD patients (n=301)
  ------------------------------------------- ---------------------
  Age, y                                      34.8±10.3
  Female, n (%)                               204 (67.8)
  Education, n (%)                            
   ≤9 years                                   62 (20.6)
   10--12 years                               111 (36.9)
   ≥13 years                                  128 (42.5)
  Marital status, n (%)                       
   Single                                     119 (39.5)
   Married/cohabitant                         182 (60.5)
  Family Income, n (%)                        
   Low                                        41 (13.6)
   Middle                                     200 (66.4)
   High                                       60 (19.9)
  BMI, n (%)                                  
   \<18.5 kg/m^2^                             77 (25.6)
   18.5--24.9 kg/m^2^                         209 (69.4)
   \>25 kg/m^2^                               15 (5.0)
  Disease location, n (%)                     
   L1 (ileal)                                 78 (25.9)
   L2 (colonic)                               82 (27.2)
   L3 (ileocolonic)                           141 (46.8)
  Disease behavior, n (%)                     
   B1 (non-stricturing, non-penetrating)      228 (75.7)
   B2 (stricturing) and/or B3 (penetrating)   73 (24.3)
  Patients with APF, n (%)                    91 (30.2)
  HBI                                         5.3±4.0
  Social-psychological index                  
   SIBDQ                                      53.3±7.5
   RSE                                        26.8±5.9
   BIS                                        8.1±3.3

###### 

Baseline demographic and clinical characteristics of CD patients with and without APF.

  Patient characteristics                     Total cohort   Propensity Score Matched cohort                                      
  ------------------------------------------- -------------- --------------------------------- --------- ----------- ------------ ---------
  Age, y                                      33.7±11.3      35.3±9.8                          0.041     33.8±10.8   32.8±10.9    0.630
  Female, n (%)                               61 (67.0)      143 (68.1)                        0.857     58 (70.7)   52 (63.4%)   0.391
  Education level, n (%)                                                                       0.067                              0.513
   ≤9 years                                   19 (20.9)      43 (20.4)                                   22 (26.8)   29 (35.4%)   
   10--12 years                               43 (47.3)      68 (32.4)                                   45 (54.9)   34 (41.5%)   
   ≥13 years                                  29 (31.9)      99 (47.1)                                   15 (18.3)   19 (23.2%)   
  Marital status, n (%)                                                                        0.438                              0.635
   Single                                     39 (42.9)      80 (38.1)                                   34 (41.5)   38 (46.3%)   
   Married/cohabitant                         52 (57.1)      130 (61.9)                                  48 (58.5)   44 (53.7%)   
  Income level, n (%)                                                                          0.336                              0.307
   Low                                        14 (15.4)      27 (12.9)                                   12 (14.6)   11 (13.4%)   
   Mediate                                    55 (60.4)      145 (69.0)                                  50 (61.0)   59 (72.0%)   
   High                                       22 (24.2)      38 (18.1)                                   20 (24.4)   12 (14.6%)   
  BMI, n (%)                                                                                   0.026                              0.181
   \<18.5 kg/m^2^                             30 (33.0)      47 (22.4)                                   25 (30.5)   19 (23.2%)   
   18.5--24.9 kg/m^2^                         59 (64.8)      150 (71.4)                                  55 (67.1)   58 (70.7%)   
   \>25 kg/m^2^                               2 (2.2)        13 (6.2)                                    2 (2.4)     5 (6.1%)     
  Disease location, n (%)                                                                      0.326                              0.963
   L1 (ileal)                                 19 (20.9)      59 (28.1)                                   18 (22.0)   20 (24.4%)   
   L2 (colonic)                               27 (29.7)      55 (26.2)                                   24 (29.3)   20 (24.4%)   
   L3 (ileocolonic)                           45 (49.5)      96 (45.7)                                   40 (48.8)   42 (51.2%)   
  Disease behavior, n (%)                                                                      0.251                              0.857
   B1 (non-stricturing, non-penetrating)      65 (71.4)      163 (77.6)                                  61 (74.4)   62 (75.6%)   
   B2 (stricturing) and/or B3 (penetrating)   26 (28.6)      47 (22.4)                                   21 (25.6)   20 (24.4%)   
   HBI                                        6.0±3.9        5.0±4.0                           \<0.001   5.8±4.0     5.9±4.3      0.971
  Social-psychological index                                                                                                      
   SIBDQ                                      51.7±8.0       54.0±7.1                          0.016     52.0±7.7    53.4±7.6     0.252
   RSE                                        23.9±5.7       28.0±5.5                          \<0.001   23.6±5.7    27.6±5.5     \<0.001
   BIS                                        9.9±2.6        7.3±3.3                           \<0.001   10.0±2.5    8.1±3.0      \<0.001

###### 

Relationship between PF remission and improvement of social-psychological status.

                              Patients with PF remission n=45   Patients with persistent APF n=41   P value
  --------------------------- --------------------------------- ----------------------------------- ---------
  PF type, n (%)                                                                                    0.046
  Simple perianal fistula     25 (55.6)                         14 (34.1)                           
  Complex perianal fistulas   20 (44.4)                         27 (65.9)                           
  Treatment, n (%)                                                                                  0.005
   With IFX                   28 (62.2)                         13 (31.7)                           
   Without IFX                17 (37.8)                         28 (68.3)                           
  Improvement of PCDAI        3.0±1.8                           −0.1±1.4                            \<0.010
  Improvement of SIBDQ        2.7±3.8                           0.4±3.0                             0.003
  Improvement of RSE          1.2±2.8                           −0.6±2.2                            0.001
  Improvement of BIS          1.2±2.4                           −0.4±1.8                            \<0.010

###### 

The role of IFX in PF remission and improvement of social-psychological status.

                         Patients treated with IFX n=41   Patients treated without IFX n=45   P value
  ---------------------- -------------------------------- ----------------------------------- ---------
  PF remission, n(%)     28 (68.3)                        17 (37.8)                           0.005
  Improvement of PCDAI   2.3±2.4                          0.9±1.9                             0.003
  Improvement of SIBDQ   2.6±3.9                          0.7±3.2                             0.015
  Improvement of RSE     1.1±2.8                          −0.4±2.5                            0.011
  Improvement of BIS     1.0±2.1                          −0.1±2.1                            0.020
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